Viking Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual Meeting of Stockholders held by Viking Therapeutics, Inc. on May 19, 2026. The record date for the meeting was March 20, 2026, with 115,893,943 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Approximately 69.1% of outstanding shares (80,089,532 shares) were represented at the meeting, constituting a quorum. Stockholders voted on three proposals:
- Proposal 1 (Director Election): Stockholders elected J. Matthew Singleton and S. Kathryn Rouan, Ph.D., as Class II directors to serve until the 2029 annual meeting.
- J. Matthew Singleton: 28,648,459 votes for; 14,562,012 votes withheld.
- S. Kathryn Rouan, Ph.D.: 21,960,203 votes for; 21,250,268 votes withheld.
- Proposal 2 (Auditor Ratification): Stockholders ratified the selection of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Votes For: 78,368,957
- Votes Against: 1,241,969
- Abstentions: 478,606
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of named executive officers.
- Votes For: 30,045,938
- Votes Against: 12,763,135
- Abstentions: 401,396
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the advisory vote on executive compensation (Proposal 3), noting the significant number of votes against (12.7 million) relative to votes for (30 million).
- Confirm the tenure and specific responsibilities of the newly elected Class II directors, J. Matthew Singleton and S. Kathryn Rouan, Ph.D.
- Review the revised definitive proxy statement filed on April 1, 2026, for detailed context on the proposals and executive compensation disclosures.
- Monitor the company's financial performance in upcoming periodic reports (10-Q/10-K) as this 8-K contains no financial data.